Compare ARK Genomic Revolution ETF (ARKG) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs First Citizens BancShares Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.1, while First Citizens BancShares Inc trades at $2,091.14 (market cap $23.94B). The key difference: First Citizens BancShares Inc pays a 0.4% dividend while ARK Genomic Revolution ETF pays none, and First Citizens BancShares Inc is trading nearer its 52-week high, ARK Genomic Revolution ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | FCNCA | |
|---|---|---|
Sector | Sector/Thematic | Sector/Thematic |
52-Week High | $43.57 | $2.20K |
52-Week Low | $23.09 | $1.64K |
Market Cap | — | $23.94B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
First Citizens BancShares (FCNCA) trades at $2,092.59, up 0.46% on the day, with a bearish technical signal but bullish moving averages. The company reported strong Q1 2026 earnings of $44.86 per share, beating estimates, and maintains a net income margin of 24.35%. Recent news highlights expansion in commercial banking and a planned rebrand of Silicon Valley Bank operations. Valuation ratios include a P/E of 12.07 and P/B of 1.2, suggesting reasonable pricing relative to earnings and book value.
The outlook for FCNCA is mixed, with solid profitability and earnings beats offset by margin pressure and credit risks. Analysts are predominantly neutral (82% hold), with a consensus price target of $2,320. Key risks include deposit volatility in tech-exposed segments and competitive pressures, while opportunities lie in continued operational execution and strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
